HALO - Halozyme Therapeutics, Inc.
Allworth Financial LP bought a new stake in Halozyme Therapeutics, Inc. (NASDAQ: HALO) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 37,664 shares of the biopharmaceutical company's stock, valued at approximately $2,948,000. Several other institutional investors have also
Halozyme stock jumps 36% in a month as strong ENHANZE-driven royalties and recently raised 2026 guidance boost investor confidence.
The GARP strategy helps investors gain exposure to stocks that have solid prospects and are trading at a discount. RL, AMP, HALO and NVDA are some such stocks.
SAN DIEGO, Aug. 18, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced the election of Dannielle Appelhans to its Board of Directors. Ms. Appelhans brings more than 20 years of executive leadership across the biotechnology and pharmaceutical industries, with deep expertise in operations, manufacturing, and supply chain management.
Major Commercialization Milestone Expands Sagtec's AI Robotics Platform into the Middle East and Establishes Initial Large-Scale Deployment Major Commercialization Milestone Expands Sagtec's AI Robotics Platform into the Middle East and Establishes Initial Large-Scale Deployment
Halozyme Therapeutics (HALO) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Here is how Halozyme Therapeutics (HALO) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year.
HALO's Q2 earnings and revenues surpass estimates, fueled by higher royalties and product sales. The company raises its 2026 outlook.
Halozyme Therapeutics NASDAQ: HALO reported record second-quarter revenue and raised its full-year outlook, citing growth in royalty income from its ENHANZE drug-delivery platform, contributions from newer product launches and revenue from newly signed collaboration agreements.
Halozyme Therapeutics, Inc. (HALO) Q2 2026 Earnings Call Transcript
Although the revenue and EPS for Halozyme Therapeutics (HALO) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Halozyme Therapeutics (HALO) came out with quarterly earnings of $2.28 per share, beating the Zacks Consensus Estimate of $1.82 per share. This compares to earnings of $1.54 per share a year ago.
Total Revenue Increased 48% YOY to $481 million Royalty Revenue Increased 50% YOY to $308 million Raises 2026 Financial Guidance Ranges: Total Revenue of $1.835 - $1.910 billion, YOY Growth of 31% - 37% Royalty Revenue of $1.220 - $1.245 billion, YOY Growth of 41% - 43% Adjusted EBITDA of $1.225 - $1.280 billion, YOY Growth of 86% - 95% 1 Non-GAAP Diluted EPS of $8.65 - $9.00, YOY Growth of 108% - 117% 1 Signed Five New ENHANZE ® and Hypercon ™ Collaboration Agreements YTD 2026, Exceeding Goal of Three for Full Year 2026 SAN DIEGO, Aug. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the second quarter ended June 30, 2026, and provided an update on its recent corporate activities. "We delivered another quarter of strong performance, with multiple proof points demonstrating the attractive features of ENHANZE as a compounding platform engine: repeatability of success, scalability, diversification and durability of revenues," said Dr. Helen Torley, President and Chief Executive Officer.
Amundi boosted its holdings in Halozyme Therapeutics, Inc. (NASDAQ: HALO) by 503.5% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund owned 121,599 shares of the biopharmaceutical company's stock after buying an additional 101,451 shares during the quarter. Amundi owned 0.10% of Halozyme Therapeutics
This medical technology name has a patented method of drug delivery. Halozyme stock recently hit a record high with earnings due out soon.
Halozyme (HALO) has delivered ~134% price appreciation since my prior 'Buy' rating in 06/2023. I evaluate whether HALO can sustain its strong growth trajectory or is due for a period of consolidation. The investment thesis centers on HALO's robust royalty revenue and product income as key growth drivers.
Halozyme Therapeutics, Inc. (NASDAQ: HALO - Get Free Report) shares reached a new 52-week high on Friday. The company traded as high as $82.99 and last traded at $81.5140, with a volume of 217609 shares trading hands. The stock had previously closed at $80.84. Analyst Ratings Changes HALO has been the topic of several analyst
SAN DIEGO, July 23, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will release its second quarter 2026 financial and operating results on Thursday, August 6, 2026, following the close of trading. Halozyme will host a conference call on Thursday, August 6, 2026 at 1:30pm PT/4:30pm ET to discuss the results.
Halozyme Therapeutics, Inc. (HALO) shares gain 539% since first Big Money outlier inflow signal in March 2014.
Halozyme grants ENHANZE rights to Incyte for developing subcutaneous cancer therapy formulations, aiming to improve treatment convenience for patients.